Armata Pharmaceuticals (ARMP) Other Non-Current Assets (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Other Non-Current Assets of $813000.0 for Q1 2026, down 84.92% sequentially from $5.4 million in Q4 2025, and down 84.92% YoY from $5.4 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Other Non-Current Assets for 11 years, with the latest figure at $813000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 84.92% year-over-year to $813000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $813000.0 (down 84.92% YoY) and the FY2025 annual result came in at $5.4 million, down 1.64% from the prior year.
- Other Non-Current Assets fell to $813000.0 in Q1 2026 per ARMP's latest filing, from $5.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $6.0 million in Q1 2022 and troughed at $813000.0 in Q1 2026.
- A 5-year average of $5.1 million and a median of $5.5 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets jumped 396.67% in 2022, then sank 84.92% in 2026.
- Over 5 years, Other Non-Current Assets stood at $6.0 million in 2022, then decreased by 4.03% to $5.7 million in 2023, then fell by 4.2% to $5.5 million in 2024, then retreated by 1.64% to $5.4 million in 2025, then tumbled by 84.92% to $813000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $813000.0, $5.4 million, and $973000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | 4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.12 Mn |
| Mar 31, 2026 | 813,000.00 |
| Dec 31, 2025 | 5.39 Mn |
| Sep 30, 2025 | 973,000.00 |
| Jun 30, 2025 | 5.39 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 5.48 Mn |
| Mar 31, 2024 | 5.48 Mn |
| Dec 31, 2023 | 5.72 Mn |
| Sep 30, 2023 | 5.82 Mn |
| Jun 30, 2023 | 5.72 Mn |
| Mar 31, 2023 | 5.72 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Sep 30, 2022 | 5.96 Mn |
| Jun 30, 2022 | 5.96 Mn |
| Mar 31, 2022 | 5.96 Mn |
| Dec 31, 2021 | 1.76 Mn |
| Sep 30, 2021 | 1.20 Mn |